After 30 years of serving the operational and professional development needs of clinical researchers, The CenterWatch Monthly presents its final issue. On behalf of myself and the editorial and production teams, I would like to thank you for your support and readership. We are grateful for the opportunity to have served you. – Leslie Ramsey, Editorial Director
The average daily cost for trials and drug development delays has dropped considerably for sponsors over the years, new data from the Tufts Center for the Study of Drug Development (CSDD) show, owing to a number of factors.
Read More
The FDA has long erred on the side of extreme caution when it comes to sharing confidential commercial information and trade secrets out of fear it might violate federal law by disclosing them.
Read More
In the rapidly evolving and competitive biotech industry, where innovation and financial performance are inextricably linked, savvy CFOs must adopt a long-term perspective to navigate the complex, often decade-long journey of drug commercialization, says Karl Dorwart, vice president, head of healthcare, life sciences and consumer staples at Factor, an integrated law provider.
Read More
While today’s technology has brought many incredible efficiencies to the clinical research landscape, tech management strategy is more important than ever before, especially at the site level. Alisha Garibaldi, CEO of Skylight Health Research, a company that runs three US sites, linked up with The CenterWatch Monthly to discuss navigating technology, her unique way of doing business, how she’s able to run her network from Canada and more.
Read More
Rare disease advocacy groups often use the phrase “rare is not rare” to drive home the point that, although individual diseases and conditions might affect only a small number of people, together they constitute a large patient population.
Read More
